Blood
Articles in this Issue
Reducing Acute Myeloid Leukemia resistance to CAR T cell therapy by epigenetic activation of the tumor inflammasome-pyroptosis signaling
Abstract Acute myeloid leukemia (AML) faces major clinical challenges characterized by high relapse and low cure rates. Chimeric antigen rec...
Clinical, cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia (APL): Real-world analysis
Abstract Introduction The advent of all-trans retinoic acid (ATRA) and arsenic trioxide revolutionized APL treatment, yet early mortality (E...
Loss of nitric oxide signaling compromises the development of the stress erythropoiesis niche
Abstract Steady-state erythropoiesis is a homeostatic process that constantly produces new erythrocytes in the bone marrow to replace senesc...
Clinical characteristics of human herpesvirus 7 (HHV-7) reactivation following umbilical cord blood transplantation: A retrospective study
Abstract Background: After allogeneic hematopoietic stem cell transplantation (allo-HSCT), immune reconstitution occurs...
Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens
Abstract Infections are a common cause of morbidity and mortality in patients with multiple myeloma (MM). Novel treatments have substantiall...
Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors
Abstract BACKGROUND Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative treatment option for patients wi...
Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial
Abstract Background: Marginal zone lymphoma (MZL) is a subtype of non-Hodgkin lymphoma. Effective, low-toxicity regimens are lacking for trea...
Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy
Abstract Background: In the ongoing global, open-label, randomized phase 3 DREAMM-7 study (NCT04246047), belantamab mafodotin, bortezomib, an...
A united-states nationwide analysis of sickle cell genotype-specific differences in inpatient outcomes
Abstract Introduction The clinical diagnosis of sickle cell disease (SCD) encompasses several genotypes. Hb-SS, Hb-SC, H...
Risk of venous and arterial thromboembolic events following CAR-T therapy in relapsed or refractory non-Hodgkin lymphoma: A propensity-matched multicenter analysis.
Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed outcomes in relapsed or refractory non-Hodgkin lymphoma...
Distinct hematologic profiles in mesoamerican versus classical chronic kidney disease: A focus on anemia, platelets, and transfusion burden
Abstract Background: Mesoamerican nephropathy (MeN) is a distinct, non-diabetic form of chronic kidney disease (CKD) primarily affecting you...
Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study
Abstract INTRODUCTION Epigenetic dysregulation is frequently associated with the pathogenesis and progression of diffuse...
Effects of ZMIZ1 mutations in newly defined early T-cell precursor leukemia
Abstract Recent large scale genomic studies of T-cell acute lymphoblastic leukemia (T-ALL) patients from the Children's Oncology Group AALL0...
Iron‑regulatory gene variants and their association with clinical phenotypes in Nigerian patients with sickle cell disease
Abstract Background: Sickle cell disease (SCD) is marked by wide variability in clinical phenotypes and severity due to environmental, clini...
Avapritinib treatment of patients with advanced systemic mastocytosis: 4-year safety, effect on bone and first-line efficacy results of the pathfinder clinical study
Abstract Introduction: Advanced systemic mastocytosis (AdvSM) is a rare clonal hematologic neoplasm mainly driven by D816V-mutant KIT. Avapr...
Overcoming resistance to bispecific antibodies through epigenetic priming in B-cell lymphoma
Abstract CD20×CD3 bispecific antibodies (BsAbs) exhibit an impressive overall response rate in several B-cell lymphomas; however, progressio...
Phase II study of bendamustine, rituximab, and venetoclax (BR-VEN) for the front-line treatment of Mantle Cell Lymphoma (MCL) in patients ≥60 years old; Updated survival and minimal residual disease (MRD) analysis of precog PrE0405
Abstract Introduction With a median age of 60-70 years at diagnosis, many patients with MCL are ineligible for aggressive treatment. Bendamus...
Heterogeneous TP53 mutation subtypes define prognostic classification in Mantle Cell Lymphoma
Abstract Background: Mantle cell lymphoma (MCL) is a biologically aggressive B-cell malignancy with marked clinical vari...
Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma
Abstract In this study, we investigated tumor intrinsic mechanisms of resistance to cevostamab, a bispecific T-cell engager targeting Fc rec...
Longer telomeres in donors aged ≥35 years reduce graft failure and non-relapse mortality after allogeneic HCT
Abstract Background Donor age is a key determinant of recipient outcomes in allogeneic hematopoietic cell transplantation (HCT), with older...
Blocking FcγRIII with anti-CD16 mab (3G8 and GMA161) increases platelets in immune thrombocytopenia: Two pilot studies
Abstract BACKGROUND Immune thrombocytopenia (ITP) is an autoantibody-mediated disorder characterized by accelerated platelet destruction and...
Acute Myeloid Leukemia eradication targeting cathepsin g with a dual HLA-restricted TCR
Abstract Background Hematopoietic stem cell transplantation has unveiled the sensitivity of acute myeloid leukemia (AML) to immunotherapy an...
Antibiotic risk score for acute graft-versus-host disease
Abstract Introduction: Certain antibiotic exposures have been associated with increased rates of acute GVHD (aGVHD) after alloHCT, likely du...
Continued risk of relapse in peripheral T-cell lymphoma even in patients who achieved complete response after initial therapy
Abstract Background: Peripheral T-cell lymphomas (PTCLs) are a rare subtype of aggressive lymphomas. Cyclophosphamide, doxorubicin, vincrist...
Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry
Abstract Introduction: Liso-cel, an autologous, CD19-directed CAR T cell product, has demonstrated consistent efficacy in a broad population...